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Abstract
Introduction: Neutrophil granulocytes are the first defense line in bacterial infections. However, granulocytes are
also responsible for severe local tissue impairment. In order to use donor granulocytes, but at the same time to
avoid local side effects, we developed an extracorporeal immune support system. This first-in-man study
investigated whether an extracorporeal plasma treatment with a granulocyte bioreactor is tolerable in patients with
septic shock. A further intention was to find suitable efficacy end-points for subsequent controlled trials.
Methods: The trial was conducted as a prospective uncontrolled clinical phase I/II study with 28-day follow-up at
three university hospital intensive care units. Ten consecutive patients (five men, five women, mean age 60.3 ±
13.9 standard deviation (SD) years) with septic shock with mean ICU entrance scores of Acute Physiology and
Chronic Health Evaluation (APACHE) II of 29.9 ± 7.2 and of Simplified Acute Physiology Score (SAPS) II of 66.2 ±
19.5 were treated twice within 72 hours for a mean of 342 ± 64 minutes/treatment with an extracorporeal
bioreactor containing 1.41 ± 0.43 × 10E10 granulocytes from healthy donors. On average, 9.8 ± 2.3 liters separated
plasma were treated by the therapeutic donor cells. Patients were followed up for 28 days.
Results: Tolerance and technical safety during treatment, single organ functions pre/post treatment, and hospital
survival were monitored. The extracorporeal treatments were well tolerated. During the treatments, the bacterial
endotoxin concentration showed significant reduction. Furthermore, noradrenaline dosage could be significantly
reduced while mean arterial pressure was stable. Also, C-reactive protein, procalcitonin, and human leukocyte
antigen DR (HLA-DR) showed significant improvement. Four patients died in the hospital on days 6, 9, 18 and 40.
Six patients could be discharged.
Conclusions: The extracorporeal treatment with donor granulocytes appeared to be well tolerated and showed
promising efficacy results, encouraging further studies.
Trial registration: ClinicalTrials.gov Identifier: NCT00818597
Introduction
Despite tremendous advances in critical care medicine,
sepsis is still a leading cause of morbidity and mortality in
non-coronary ICUs. In the USA, approximately 215,000
patients die each year as a consequence of sepsis [1]. The
often unsuccessful efforts to rescue septic patients in ICU
are extremely expensive and costs are approaching US $17
billion annually in the United States [1].
The underlying deregulated immune mechanisms that
lead to the development of sepsis are highly complex
and involve both overshooting inflammatory responses
of the innate immune system and the lack of adequate
anti-microbial immune responses both by the innate
and adaptive arm of immunity. In particular, neutro-
phils, the prototype of non-specific early anti-microbial
effector cells, may lead to collateral damages such as
disruption of endothelial integrity and impairment of
microcirculation within organs, for example, by overpro-
duction of proteases and oxygen radicals [2-4]. On the
other hand, the physiological effector functions of
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microbial load. Moreover, functional impairment of neu-
trophils and other immune cells has been shown to be
associated with increased mortality in advanced stages
of sepsis and septic shock [5-7].
In the past, efforts to stimulate the innate immune
system with granulocyte-colony stimulating factor (G-
CSF), granulocyte-macrophage-colony stimulating factor
(GM-CSF) or interferon gamma (IFN-gamma) in septic
patients failed to decrease mortality rates in septic
patients. However, except for neonates, no sufficiently
powered studies were performed in this field [8-10].
Likewise, the transfusion of granulocyte preparations
(GTx) failed to improve survival in sepsis and neutrope-
nia [11,12]. Nevertheless, there is some indication that
steroid- or G-CSF-stimulated high-yield granulocyte-
donations might result in better survival in severe infec-
tions associated with neutropenia and cancer [12,13].
In order to deploy the beneficial features of neutro-
phils such as phagocytosis of cellular debris, antigenic
material or pathogens, and at the same time to circum-
vent the possible damaging local effects of systemically
transfused neutrophils, a bed-side bioreactor was devel-
oped, that uses granulocytes in a strictly extracorporeal
mode. This bioreactor consists of a plasma separating
device and an extracorporeal circuit containing donor
neutrophils. The patient is connected to the extracor-
poreal circuit for the whole treatment. Plasma from sep-
tic patients is perfused through the neutrophil housing
and the treated plasma is re-infused online into the
patient. The bioreactor-cells are retained in the extra-
corporeal system and discarded after the treatment.
In in vitro studies [14] and in a large animal model for
Gram-positive sepsis [15], we were able to show the
proof of principle and promising survival data. There-
fore, the bioreactor is now being studied in patients
with septic shock in order to show tolerability and feasi-
bility of this kind of complex therapy. Furthermore, this
pilot trial should give hints for relevant end points to
adequately power a subsequent controlled study. This is
the first report showing data from a pilot study on ICU
on the efficacy and tolerability of a granulocyte bioreac-
tor system.
Materials and methods
The study was conducted in accordance with the Hel-
sinki Declaration, received ethics approval from the
local research ethics committee, and the state authorities
were notified according to German pharmaceutical and
medical device law. The trial has been registered at
ClinicalTrials.gov under reg.-no: NCT00818597. Written
informed consent was obtained from all participants or
from the patients’ representatives if direct consent could
not be obtained.
Patients
During a four-month period all patients of one medical
and two surgical intensive care units of a tertiary care
university hospital were screened to see if they fulfilled
the parameters of severe sepsis and septic shock as
defined by international consensus criteria [16]. Defini-
tions of organ dysfunctions were adopted from the
“Recombinant Human Activated Protein C Worldwide
Evaluation In Severe Sepsis Study” (PROWESS Study)
[17] with the difference being that liver failure was not
an exclusion criterion in this current study. The exclu-
sion criteria were age under 18 years, hepatitis C, active
bleeding and HIV infection. Ten consecutive patients
with septic shock were enrolled in the study.
Procedures
The study flow is depicted in Figure 1. After inclusion of
a patient, a healthy blood donor was identified and sti-
mulated with corticosteroids (each 20 mg p.o. methyl-
prednisolone, Sanofi-Aventis Deutschland GmbH,
Frankfurt, Germany) 17 h, 12 h and 2 h before donation
of an ABO-compatible granulocyte concentrate. Granu-
locytes were collected by extracorporeal density gradient
centrifugation using hydroxyethylstarch (HES 200/0.5
6%, Fresenius Kabi AG, Bad Homburg, Germany) and
citrate in a cell separator (COBE Spectra, Gambro BCT,
Planegg-Martinsried, Germany) according to standard
procedures. Because of the delay due to identification
and stimulation of a compatible donor the first treat-
ment of a patient was one day after inclusion in four
cases, two days after inclusion in three cases, and three
days after inclusion in two cases. Prior to treatment the
inclusion criteria were re-confirmed. The whole extra-
corporeal system was first rinsed and prefilled with
hemofiltration solution HF-BIC 35-410 with 4 mM
potassium (Fresenius Medical Care, Bad Homburg, Ger-
many). In mean 1.41 ± 0.43 × 10E10 donor granulocytes
were delivered in donor plasma and were placed into
the bioreactor compartment of the device prior to con-
nection to the patient. An excess of hemofiltration solu-
tion during cell filling was discarded; therefore, no
additional fluid was infused into the patient. The
patients were treated for up to six hours with an extra-
corporeal method consisting of a plasma separation and
plasma perfusion through the cell-compartment contain-
ing the donor cells. Blood access was veno-venous via a
Shaldon-catheter. Plasma separation was carried out by
a dialysis monitor (BM25, Edwards Lifesciences GmbH,
Unterschleissheim, Germany) using a 0.5 μmp o r e - s i z e
plasma filter (PF 1000N, Gambro Hospal GmbH, Pla-
negg-Martinsried, Germany). The plasma was infused
into the continuously re-circulating donor cell compart-
ment. A schematic view of the extracorporeal treatment
device is shown in Figure 2. Plasma reflux to the patient
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withhold the donor cells from being infused into the
patient. Total extracorporeal volume was 400 ml. The
blood flow rate was 150 to 200 ml/minute with a plasma
separation rate of 16.7 to 33.3 ml plasma/minute using the
BM 25 monitor. The MARS-Monitor 1 TC (Gambro
Rostock GmbH, Rostock, Germany) was used for the re-
circulating bioreactor circuit at a rate of 200 ml/minute
and to maintain the temperature in the cell compartment
at 37°C. Unfractionated heparin (20 IU/kg, Roche, Gren-
zach-Wyhlen, Germany) was given at the beginning of the
extracorporeal treatment followed by a continuous infu-
sion into the circuit. Heparin administration was adjusted
to maintain activated clotting time (ACT) between 150 to
200 seconds. Following tolerability assessment of the first
treatment, all patients were treated a second time 48 to 72
hours after the first treatment, again for up to 6 hours
with granulocytes from the same donor.
Measurements
We recorded basic demographic information, illness
severity (Acute Physiology and Chronic Health Evalua-
tion (APACHE) II, Sequential Organ Failure Assessment
(SOFA), Multiple Organ Dysfunction Score (MODS),
and Simplified Acute Physiology Score (SAPS) II scores),
microbiological results, pre-morbidity, and clinical out-
come for the study cohort (see Table 1). Patients were
followed up for 28 days and hospital survival. At the
days “inclusion”, 1 to 8, 10, 12, 14, 21, 28 and before/
after an extracorporeal bioreactor-treatment the patients
Admission at ICU
Screening  for fitting inclusion and exclusion criteria
written informed consent
Inclusion
Search for ABO-compatible granulocyte donor
Stimulation of donor with corticosteroids for 17h
granulocyte donation
Controlling for fitting inclusion and exclusion criteria
First 6h treatment
Safety evaluation
Second 6h treatment
Observation period till „day 28“
Evaluation of hospital survival
„day 1“
at day 3 or 4
at day 2
Figure 1 Schematic view of the study flow.
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hemodynamic, inflammation, coagulation, hemolysis,
temperature, organ function blood parameters, endo-
toxin, cytokines, complement (C3, C4), and the number
of human leukocyte antigen DR (HLA-DR) molecules
per monocyte surface. “Day 1” was defined as the day of
the first bioreactor treatment. Viability and functionality
of the donor cells were tested at the begin and end of
the treatments by trypan blue test, phagocytosis by flow
cytometry (Beckman Coulter Immunotech, Krefeld, Ger-
many) with florescence-labeled E. coli and oxyburst
both by flow cytometry with dihydrorhodamine 123 as
well as in a luminometer (Thermo Labsystems, Wal-
tham, MA, USA) with luminol and lucigenin.
Statistical analysis
T h eS t a t i s t i c a lP a c k a g ef o rt h eS o c i a lS c i e n c e s( S P S S ,
IBM Corporation, Somer, NY, USA) was used to con-
duct nonparametric analyses using the Friedman-test
and Wilcoxon-test. In addition to the evaluation of the
raw data, a Last Observation Carried Forward (LOCF)
analysis was performed to limit the bias due to the
dropout of the three non-survivors during the 28 days
observation period. The results are expressed as the
mean ± standard deviation (SD). Differences were con-
sidered significant at P < 0.05.
Results
Patients
Ten consecutive patients with septic shock were
included in the study. Details concerning diagnoses, age,
sex, relevant scores and survival are shown in Table 1.
All patients had positive microbial tests with a mean of
4.7 ± 2.6 different microbial species per patient, predo-
minantly candida, coagulase negative staphylococcus,
enterococcus and E. coli.
Observations during the treatments: technical results
During the first treatment performed in this study the
heparin use was adjusted to a target ACT of 125 to 150 sec.
Bioreactor
Donor
Granulocytes
Plasma-
Separator 2
(Filter)
Plasma-
Separator 1
(Filter)
Blood Plasma
Figure 2 Schematic drawing of the extracorporeal treatment. Plasma is separated from blood, transferred to the cell-compartment, and then
returned to the patient.
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ment had to be terminated. Therefore, in all further treat-
ments the heparin dosage was adjusted according to a
target ACT of 150 to 200 sec. Except for Patient 6 where
treatment #2 had to be terminated after five hours due to
increased transmembranal pressure across the cell filter, all
other treatments were carried out for six hours. Mean
treatment time was 342 ± 64 minutes. Blood flow varied
from 150 to 200 ml/minute depending on the patient’s
quality of blood access. The flow rate in the cell therapy cir-
cuit was 200 ml/minute. Plasma flow started with 16.7 ml/
minute for the first 15 to 30 minutes and then increased to
33.3 ml/minute. A mean of 9.8 ± 2.5 liters of plasma were
treated during each of the 20 treatments. To test whether
the donor cells were still functional every two hours, cells
from the cell circuit were evaluated for viability and func-
tionality. For the whole treatment the cells showed a viabi-
lity of more than 90% and unimpaired cellular functions
like phagocytosis and oxidative burst.
Primary endpoints (safety): hemodynamic
During the extracorporeal procedures, no significant
drop in mean arterial pressure was observed. All
patients were on noradrenaline at the beginning of the
first treatment and five of these patients also received it
at the start of the second treatment. In 10 of the 20 pro-
cedures the noradrenaline dose could be reduced due to
an increase in the mean arterial pressure. In five treat-
ments the noradrenaline dose remained unchanged.
Only in one case (Patient 4, second treatment) the nora-
drenaline infusion that had been turned off before the
treatment was turned on again during the treatment,
however, at a small dose (0.03 μg/kg/minute). Overall
the Wilcoxon test showed a significant reduction in the
noradrenaline dose (median from 0.06 to 0.035 μg/kg/
minute; P = 0.016; Table 2) while the mean arterial
pressure was stable during the bioreactor-treatment
(median before 74, after 80 mmHg; not significant). Sys-
temic vascular resistance index (SVRI) was not moni-
tored in this study.
Coagulation disorders
There was no significant change in mean platelet counts
during the extracorporeal treatment (Table 2). D-dimers
did increase significantly during the extracorporeal treat-
ment from 752 ± 505 μg/l to 853 ± 450 μg/l but
returned to 609 ± 381 μ/l within 12 hours. Antithrom-
bin III concentration also changed significantly from 66
Table 1 Patients characteristics, illness severity, premorbidity and clinical outcome for study cohort (n = 10)
Patient Major diagnoses
at inclusion
Premorbidity APACHE
II at ICU
arrival
SOFA at ICU
arrival/at
inclusion
SAPS II at
ICU arrival/
at inclusion
Hospital
survival
Inclusion
at ICU
day
Time between
inclusion and first
treatment in days
1 Pneumonia, ALI, SS Alcohol abuse 37 15/16 96/80 Survived 1 2
2 Necrotizing
pancreatitis,
Pneumonia, SS
Alcohol abuse 27 12/11 61/61 Survived 9 1
3 Pneumonia, ALI,
Urogenital
infection, SS
Ischemic heart disease,
Hydrocephalus, brain-tumor
operation
30 12/11 66/58 Died
(Day 18)
31
4 ALI, SS, Liver failure Liver cirrhosis, COPD,
Diabetes mellitus
37 17/17 72/73 Died
(Day 9)
10 1
5 Cardiopulmonary
resuscitation, ALI,
SS
Alcohol abuse,
Encephalopathy, Ischemic
heart disease
36 11/13 83/66 Survived 4 1
6 Mediastinitis, SS Alcohol abuse 27 14/13 70/63 Survived 1 2
7 Hip joint
endoprosthesis
infection, SS
Diabetes mellitus 21 8/6 35/35 Died
(Day 40)
13
8 Postoperative
shock after ACB-
surgery, ARF, SS
Ischemic heart disease,
Cardiac failure
38 13/9 74/50 Survived 6 12
9 Renal failure,
Kidney infection,
SS
Polycystic Kidney and Liver 29 8/12 72/31 Survived 3 2
10 Thoracic infection
after sternum
resection, ARF, SS
Radio-Necrosis of Sternum
after Radio-Chemotherapy
due to Breast Cancer
17 8/11 33/70 Died
(Day 6)
27 3
Median 29 12/11 70/61 4 2
Mean 29.9 11.8/11.9 66.2/58.7 6.5 2.8
ACB, aortocoronary bypass, ALI, acute lung injury, ARF, acute renal failure, COPD, chronic obstructive pulmonary disease, SS, septic shock.
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treatments, and improved slightly over the following 12
h to 61 ± 15%. Both activated partial thromboplastin
time (aPTT) and prothrombin time (as International
Normalized Ratio, INR) increased during the treatments
due to heparin use but returned to pre-treatment values
within 12 h after the extracorporeal circulation. No
hemorrhages were observed.
Hemolysis
No signs of hemolysis were observed. Haptoglobin
remained within the normal range and no significant
change in lactate dehydrogenase was seen during the
treatments.
Moreover, no allergic reactions were recognized.
Secondary endpoints (safety and efficacy): comparison of
projected and observed mortality
Expected in-hospital mortality based on the ICU
entrance APACHE II (29.9 ± 7.2) and SAPS II (66.2 ±
19.5) scores were 69.1% and 71.5%, respectively [18-20].
The observed mortality rate was 3 out of 10 within 28
days (on days 6, 9, and 18), and four during hospital
stay (Patient 7 died on Day 40). Six patients could be
discharged from the hospital in stable condition. No sig-
nificant differences were seen between the survivors and
non-survivors in the time at ICU before inclusion or the
time between inclusion and first treatment.
Organ functions, vital signs and laboratory parameters
The body temperature of the patients was stable during
the treatments (Table 2). While creatinine did not show
a significant change during the six-hour treatments
there were small but significant increases in urea (Table
2), most probably due to interruption of dialysis in
patients with renal failure. However, urea decreased
again slightly within 12 h post treatment to 14.7 ± 8.4
mmol/l. No difference in PaO2 and FiO2 has been
observed between start and end of the extracorporeal
treatment (Table 2). Furthermore, no significant changes
have been seen in PaO2 or FiO2 between the treatment
day and the day after the treatment.
Inflammation
During the six-hour treatment a dramatic increase in
white blood cell (WBC) counts was observed (Table 2).
Table 2 Main laboratory parameters before and after the extracorporeal treatments
Parameter Unit Before extracorporeal treatment n = 20 After 6 h extracorporeal treatment n =2 0 P-value
Inflammation
Leukocytes Gpt/l 12.2 ± 6.6 20.8 ± 12.4 P < 0.01
Banded neutrophils % 73 ± 11 70 ± 10 n.s.
Segmented neutrophils % 18 ± 11 18 ± 12 n.s.
C-reactive protein mg/l 190 ± 130 165 ± 119 P < 0.01
Procalcitonin ng/l 10.1 ± 23.4 6.8 ± 14.6 P < 0.01
Endotoxin pg/ml 16.4 ± 7.7 13.5 ± 5.5 P < 0.05
Temperature °C 36.86 ± 0.97 36.73 ± 0.87 n.s.
Hemodynamic
Noradrenaline μg/kg/minute 0.10 ± 0.12 0.08 ± 0.10 P< 0.05
MAP mmHg 76.9 ± 12.8 80.2 ± 9.8 n.s.
Pulse bpm 101 ± 19 101 ± 20 n.s.
Respiration
PaO2 kPa 13.0 ± 3.1 13.4 ± 4.0 n.s.
FiO2 % 40.8 ± 19.4 40.0 ± 16.3 n.s.
Coagulation
INR 1.29 ± 0.25 1.44 ± 0.29 P < 0.01
aPTT sec 53.8 ± 50.2 85.8 ± 47.4 P < 0.05
Antithrombin III % 65.6 ± 16.8 58.4 ± 15.3 P < 0.01
Fibrinogen g/l 5.07 ± 2.25 4.62 ± 2.15 P < 0.01
D-Dimere μg/l 752 ± 505 853 ± 450 P < 0.05
Platelets Gpt/l 163 ± 130 169 ± 152 n.s.
Other
Urea mmol/l 13.5 ± 7.5 15.0 ± 8.4 P < 0.01
Creatinin μmol/l 129 ± 99 132 ± 108 n.s.
Bilirubin μmol/l 33.1 ± 44.2 35.4 ± 44.8 n.s.
MAP, Mean arterial pressure; INR, International normalized ratio; aPTT, Activated partial thromboplastin time
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subset of WBC, the ratio of segmented to banded neu-
trophils remained unchanged. Furthermore, there was a
significant decrease in plasma endotoxin concentration
from pre- to post-treatment (Table 2). In 11 of the
tested cytokines a significant increase pre vs. post cell-
bioreactor was observed (IL-2,-4,-8,-10,-1beta,-12, IP-10,
Interferon gamma, Eotaxin, PDGF, RANTES). This
resulted in significant increases pre- vs. post-treatment
in the patients’ plasma in 5 out of these 11 cytokines
(IL-8,-10,-1beta, Eotaxin, RANTES) (Table 3). Moreover,
there were significant decreases both in CRP as well as
in PCT during the treatments (Table 2).
Results of the 28-day observation period
The statistical evaluation of the raw data showed
improvements in several parameters evaluated during
the 28 days of observation. The main findings include:
significant reduction in CRP (Figure 3), PCT (Figure 4)
and IL-8 (not shown); significant increase in HLA-DR
on CD14-positive monocytes (Figure 5); significant
increase in platelets and antithrombin III (not shown);
significant reduction in noradrenaline use (Figure 6);
significant reduction in alanine transaminase, aspartate
transaminase and creatinine (not shown); and signifi-
cant reduction in MODS and SOFA scores (not
shown).
Out of these parameters PCT values, Noradrenaline
dosage and SOFA score showed improvement already
prior to the first treatment and further improved during
the observation period.
In order to limit the bias due to the dropout of the
non-survivors, an additional LOCF analysis was per-
formed that also showed significant improvements for
CRP, PCT, HLA-DR, noradrenaline, and creatinine.
Due to the large inter-individual differences no signifi-
cant changes in leukocyte counts were seen except
directly before and after treatment (see above).
Table 3 Changes in cytokine concentrations in patients’ bood (left side) and in the extracorporeal circuit (right side)
Patient Extracorporeal circuit during treatment
Mediator Before extracorporeal
treatment
After 6 h extracorporeal
treatment
% P Directly before cell
compartment
Directly behind cell
compartment
% P
IL-2 3.67 11.92 325 n.s. 0.78 1.42 182 < 0.05
IL-4 0.87 2.29 263 n.s. 0.09 0.24 268 <0.001
IL-6 102.22 313.15 306 n.s. 226.06 299.38 132 n.s.
IL-8 20.39 41.31 203 <0.05 31.79 165.15 520 <0.001
IL-10 2.57 6.54 254 <0.01 3.86 6.02 156 <0.05
IL-1 beta 1.21 2.12 175 <0.05 0.74 1.11 150 <0.05
IL-5 0.42 1.33 315 n.s. 0.39 0.52 135 n.s.
IL-7 3.19 5.19 163 n.s. 2.64 4.14 157 n.s.
IL-12(p70) 2.46 9.65 392 n.s. 0.09 0.45 498 <0.001
IL-13 1.68 3.34 199 n.s. 0.85 1.05 124 n.s.
IL-17 0.05 0.59 1185 n.s. 0.04 0.10 274 n.s.
IL-1ra 106.96 208.03 194 n.s. 113.40 134.53 119 n.s.
IL-15 4.19 6.35 151 n.s. 3.20 4.37 136 n.s.
IL-9 1.11 8.15 737 n.s. 0.29 0.78 265 n.s.
IP-10 240.16 561.57 234 n.s. 508.51 749.08 147 <0.05
G-CSF 30.84 43.73 142 n.s. 50.87 53.44 105 n.s.
GM-CSF 10.81 50.79 470 n.s. 1.52 3.41 224 n.s.
IFN
gamma
50.29 79.07 157 n.s. 14.83 25.26 170 <0.05
TNF alpha 0.00 0.00 100 n.s. 0.81 0.19 24 n.s.
MCP-1
(MCAF)
130.72 224.46 172 n.s. 299.52 225.67 75 n.s.
MIP-1b 55.93 98.89 177 n.s. 76.92 103.23 134 n.s.
Eotaxin 85.64 216.82 253 <0.05 80.23 130.72 163 <0.01
FGF basic 1.51 9.47 629 n.s. 0.61 0.00 0 n.s.
PDGF bb 652.01 1145.02 176 n.s. 10.28 62.25 606 <0.001
RANTES 137.70 298.64 217 <0.05 22.91 141.43 617 <0.001
VEGF 168.92 198.68 118 n.s. 1.12 2.45 219 n.s.
MIP-1
alpha
0.39 1.00 253 n.s. 0.34 0.51 148 n.s.
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Today’s best treatment of sepsis includes early and
aggressive antibiotic therapy and effective support for
failing organ systems including metabolic stability and
maintenance of stable hemodynamic [21]. Immunomo-
dulation has been introduced as an adjunctive therapeu-
tic approach to overcome immune system dysfunction
and could show positive impact on survival in some stu-
dies [22] but failed in a number of other studies [23,24].
Extracorporeal blood detoxification methods have also
been suggested to successfully influence immune imbal-
ances and subsequently clinical course and outcome of
multi-organ failure and sepsis [25]. High volume hemo-
filtration [26], high cut-off hemofiltration [27], high
adsorption hemofiltration [28]; coupled plasma filtration
adsorption (CPFA) [29]; plasma- or whole blood perfu-
sion through adsorptive columns [30]; and plasma or
whole blood exchange have been proposed (for review
see [31,32]). Cytokines, for example, can be significantly
reduced in the circulation of septic patients by extracor-
poreal treatments. Techniques capable of removing lar-
ger molecules/particles from plasma (that is, high-
volume treatments, large-pore filtration, plasmapheresis
and adsorption) appear to have a stronger impact on
clinical course and outcome than techniques primarily
addressing smaller water-soluble molecules [29,33].
Extracorporeal bioreactors were studied in the treat-
ment of various diseases. Acute liver failure [34] and
acute renal failure associated with sepsis [35] have been
targeted by different cell-based extracorporeal organ
support systems using hepatocytes or renal tubular cells.
Proper choice of the cell-source turned out to be of cen-
tral importance [36]. However, the use of immune cells
to treat sepsis in an extracorporeal setting has not been
reported so far.
Allogeneic blood transfusions have been implicated to
increase the risk of nosocomial infections and are inde-
pendently associated with increased length of stay and
mortality in critically ill patients [37]. Leukocytes are
thought to trigger this effect and leuko-reduction of
blood transfusions was found to result in a decrease of
infections and mortality in post-operative intensive care
[38]. Therefore, the intravenous transfusion of leuko-
cytes remains under controversial discussion.
In a pig study of Staphylococcus aureus-induced sep-
sis, the extracorporeal granulocyte-treatment resulted in
Study days
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Page 8 of 13significant improvement of one-week survival as com-
pared to both the untreated and the sham control. The
effect on survival was dependent on the presence of
granulocytic HL-60 cells in the bioreactor device. In the
sham-bioreactor-treated group no survival benefit was
observed [15].
In this current study 10 patients with septic shock
were treated. The plasma of the patients had a strong
inhibitory effect on the functionality (that is, oxyburst)
of myeloid cell lines, indicating a neutrophil function-
inhibiting milieu in all patients (data not shown). This is
in line with reports in the literature [7].
The extracorporeal cell-treatment was well tolerated
both with regard to technical safety of the procedure as
well as the biocompatibility of the allogeneic bioreactor-
cells. No adverse effects were noted that could be
accounted for by the presence of the human phagocytic
cells. Specifically, no unwanted effects were observed in
the function of the lungs or other organs as were
reported following GTx-treatments.
The dosage of anticoagulation needed to be increased
following an episode of clotting observed during the
first single treatment. For all following treatments a
higher target ACT was adopted. After the adaptation,
no clotting or increased bleeding episodes were
observed.
The hemodynamic situation of the patients improved
significantly through the course of the treatment. This is
a remarkable finding as other extracorporeal blood
treatments such as renal replacement therapies can
induce hypotension and other unwanted effects in criti-
cally ill patients [39]. There is a correlation between
vasopressor load and mortality in septic shock patients
[40]. Thus, reduction of vasopressor load might be a
valuable parameter for future clinical studies with the
bioreactor device.
The increase in leukocyte count after six hours of
treatment is one of the results that appear to be a direct
effect of the bioreactor perfusion. It most likely is the
consequence of a cytokine influx from the bioreactor.
However, no clinically unwanted effect of this leukocy-
tosis was observed, neither directly following treatment
nor in the following days (that is, no organ dysfunction,
especially no notable lung injury). This might be due to
the “balanced” cytokine influx with both pro- and anti-
inflammatory cytokines (compare Table 3).
The 28-day results indicate stabilization of conditions
in seven patients including normalization of the
Study days
P
r
o
c
a
l
c
i
t
o
n
i
n
 
i
n
 
n
g
/
m
l
0
20
40
60
80
100
120
140
160
Incl    1      2     3      4     5      6      7     8     10    12    14    21   28
* § * § * § * § * § * § * § * § * § * § * § * § *
Figure 4 Box plots of data describing the time course of procalcitonin. Significant changes (P < 0.05) vs. inclusion day (indicated by *) and
vs. Day 1 (§) were observed.
Altrichter et al. Critical Care 2011, 15:R82
http://ccforum.com/content/15/2/R82
Page 9 of 13inflammatory situation and reversal of organ failure,
resulting in seven 28-day survivors and six hospital sur-
vivors. However, no conclusions about survival can be
drawn based on this uncontrolled pilot study. Moreover,
the favorable clinical course of the majority of patients
cannot be linked only to the bioreactor treatments
based on the present data. They might just reflect the
natural course of the disease and the impact of proper
standard intensive care treatment. Future clinical inves-
tigations will be needed to address these questions.
The mechanism of action of the device remains
incompletely understood at present. The efficient
removal of live bacteria by granulocytes was both pro-
ven in vitro and in the pig-bacteremia model [14,15].
There is already good evidence for removal of bacterial
endotoxins as well as interaction on the mediator and
cytokine level during this clinical study. This is in line
with observations from the pig model [15]. Interestingly,
the bioreactor cells released a mixture of pro-inflamma-
tory as well as anti-inflammatory cytokines. The interac-
tions on the cellular and mediator level will be another
task to study in future clinical trials.
The present study has several limitations. As an
uncontrolled pilot study it does not carry the capacity to
answer any questions regarding clinical course or out-
come of the patients. Further controlled studies in larger
patient cohorts will need to address these questions.
Although no severe unwanted effects were observed
during the treatments, no final conclusion on the safety
can be drawn based on the results from 20 single treat-
ments in 10 patients. The course of biomarkers of
inflammation and cytokines needs further investigation
as well. The apparent link between fall in CRP and PCT
following the bioreactor treatments needs to be sepa-
rated from the effects induced by standard intensive
care including application of antibiotics. The mechanism
of cytokine response of the bioreactor needs further elu-
cidation. The observed influx of pro- and anti-inflamma-
tory cytokines into the patient surely is one of the most
interesting results of this study. However, it has to be
carefully followed in further investigations and its
impact on patient’s safety should be monitored closely.
At present extracorporeal detoxification methods
already play an important role in intensive care therapy
of septic multi organ failure, for example, as renal and
liver dialysis [41]. A combination of various extracorpor-
eal support approaches appears as an interesting option
for future organ support strategies.
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The objective of the current study was to deploy donor
granulocytes in patients with septic shock and immune
cell-paralysis in a strictly extracorporeal setting and,
thereby, prevent potential local side effects in the
inflamed tissue.
In summary, the results of the present study mainly
indicate three things: a) extracorporeal plasma-treatment
with granulocytic cells is well tolerated in critically ill
patients with septic shock, b) treatment was associated
with significant improvement of the hemodynamic situa-
tion of the patients, and c) clinical courses of the
patients in this pilot study encourage further clinical
studies with this therapeutic approach.
Key messages
￿ A bedside-bioreactor with donor granulocytes was
clinically tested in 10 patients with septic shock.
￿ Every patient was treated twice for six hours each.
The treatments were tolerated well by the patients.
￿ The bioreactor cells released a mix of pro- and
anti-inflammatory cytokines that had an impact on
the cytokine levels in the patient.
￿ Parameters describing immune cell function (HLA-
DR), inflammation status (CRP, PCT, WBC), hemo-
dynamics (vasopressor dosage) of the patients
improved during the treatment.
￿ Labchemical and clinical results encourage further
clinical studies.
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